"The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system. The drug receiv"...
The maximum tolerated dose of NEUPOGEN has not been determined. In NEUPOGEN clinical trials of patients with cancer receiving myelosuppressive chemotherapy, WBC counts > 100,000/mm³ have been reported in less than 5% of patients, but were not associated with any reported adverse clinical effects. Patients in the BMT studies received up to 138 mcg/kg/day without toxic effects, although there was a flattening of the dose response curve above daily doses of greater than 10 mcg/kg/day.
NEUPOGEN is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim or pegfilgrastim [see WARNINGS AND PRECAUTIONS].
Last reviewed on RxList: 2/19/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Neupogen Information
Neupogen - User Reviews
Neupogen User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.